Evaluation of ASP3082 in Adult Patients with Advanced Solid Tumors

The primary objective of this study is to evaluate the efficacy and safety of **ASP3082** in adults with advanced **solid tumors**. This is clinically relevant as it aims to provide insights into potential therapeutic options for patients with these challenging malignancies, where treatment options may be limited. The study seeks to determine the impact of ASP3082 on tumor progression and patient outcomes, contributing to the understanding of its role in cancer management.

The clinical trial involves a total of **451 participants** diagnosed with **solid tumors**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet or physical activity. The selection process for the trial population is not explicitly described, and no principal inclusion criteria are provided. The general health status of participants is not detailed beyond the presence of solid tumors.

The clinical trial is designed to evaluate the safety and efficacy of a new investigational product in adults with **advanced solid tumors**. This study is a Phase 1 trial, which is typically the first stage of testing in human subjects and focuses on assessing the safety profile, dosage range, and potential side effects of the investigational product. The trial is structured as a randomized, double-blind, controlled study to ensure the reliability and validity of the results. The estimated duration of the trial is from January 1, 2024, to June 30, 2026, allowing for comprehensive data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a thorough medical assessment, including a review of medical history and relevant diagnostic tests. Once enrolled, participants will attend regular follow-up visits at specified intervals to monitor their health status, assess the investigational product's effects, and collect necessary data. These visits are crucial for ensuring participant safety and evaluating the investigational product's impact on the disease. The study will conclude with an end-of-study visit, where final assessments will be conducted, and participants will be debriefed on their involvement in the trial.

The expected length of participant involvement in the trial will vary depending on individual response and the investigational product's effects. However, participants are generally expected to remain in the study for the entire duration unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the investigational product, withdrawal of consent, or any other medical or personal reasons deemed significant by the study investigators. The trial's design and procedures are meticulously planned to ensure the highest standards of scientific rigor and participant safety throughout the study period.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of January 1, 2024, and an estimated end date of June 30, 2026. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's impact. The methods and schedule for measuring efficacy will be aligned with standard clinical trial practices, ensuring rigorous assessment of the investigational product's effects. The trial will adhere to established protocols to ensure the reliability and validity of the efficacy data collected throughout the study duration.